NasdaqGS - Delayed Quote USD

MaxCyte, Inc. (MXCT)

Compare
4.4300 +0.2400 (+5.73%)
At close: December 11 at 4:00:01 PM EST
4.5400 +0.11 (+2.48%)
After hours: December 11 at 6:05:17 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
45,599.0000
41,288.0000
44,261.0000
33,894.1000
26,168.9000
Cost of Revenue
6,392.0000
4,742.0000
5,098.0000
3,647.4000
2,767.0000
Gross Profit
39,207.0000
36,546.0000
39,163.0000
30,246.7000
23,401.9000
Operating Expense
85,599.0000
84,845.0000
66,524.0000
48,435.3000
34,458.6000
Operating Income
-46,392.0000
-48,299.0000
-27,361.0000
-18,188.6000
-11,056.7000
Net Non Operating Interest Income Expense
10,656.0000
10,376.0000
3,917.0000
-893.6000
-759.7000
Other Income Expense
--
--
-127.0000
--
--
Pretax Income
-35,736.0000
-37,923.0000
-23,571.0000
-19,082.2000
-11,816.4000
Net Income Common Stockholders
-35,736.0000
-37,923.0000
-23,571.0000
-19,082.2000
-11,816.4000
Diluted NI Available to Com Stockholders
-35,736.0000
-37,923.0000
-23,571.0000
-19,082.2000
-11,816.4000
Basic EPS
-0.34
-0.37
-0.23
-0.21
-0.17
Diluted EPS
-0.34
-0.37
-0.23
-0.21
-0.17
Basic Average Shares
104,388.0140
103,268.5020
101,702.6640
90,619.0570
69,464.7510
Diluted Average Shares
104,388.0140
103,268.5020
101,702.6640
90,619.0570
69,464.7510
Total Operating Income as Reported
-46,392.0000
-48,299.0000
-27,361.0000
-18,188.6000
-11,056.7000
Total Expenses
91,991.0000
89,587.0000
71,622.0000
52,082.7000
37,225.6000
Net Income from Continuing & Discontinued Operation
-35,736.0000
-37,923.0000
-23,571.0000
-19,082.2000
-11,816.4000
Normalized Income
-35,736.0000
-37,923.0000
-23,571.0000
-19,082.2000
-11,816.4000
Interest Income
10,656.0000
10,376.0000
3,917.0000
150.8000
65.9000
Interest Expense
116.0000
--
126.9000
1,044.4000
825.6000
Net Interest Income
10,656.0000
10,376.0000
3,917.0000
-893.6000
-759.7000
EBIT
-46,392.0000
-48,299.0000
-27,361.0000
-18,037.8000
-10,990.8000
EBITDA
-42,032.0000
-44,128.0000
-24,663.0000
-16,613.9000
-9,943.1000
Reconciled Cost of Revenue
6,218.0000
4,556.0000
4,928.0000
3,572.6000
2,744.4000
Reconciled Depreciation
4,360.0000
4,171.0000
2,698.0000
1,423.9000
1,047.7000
Net Income from Continuing Operation Net Minority Interest
-35,736.0000
-37,923.0000
-23,571.0000
-19,082.2000
-11,816.4000
Normalized EBITDA
-42,032.0000
-44,128.0000
-24,663.0000
-16,613.9000
-9,943.1000
12/31/2020 - 7/30/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

HYPR Hyperfine, Inc.
0.9950
+0.48%
 
TMCI Treace Medical Concepts, Inc.
7.83
-0.89%
 
CLPT ClearPoint Neuro, Inc.
16.43
-1.50%
 
PROF Profound Medical Corp.
7.55
-2.08%
 
INGN Inogen, Inc.
9.64
-0.41%
 
AORT Artivion, Inc.
29.92
+0.30%
 
APYX Apyx Medical Corporation
1.8500
+0.54%
 
IART Integra LifeSciences Holdings Corporation
24.15
+0.58%
 
XAIR Beyond Air, Inc.
0.4826
-0.35%
 
CTKB Cytek Biosciences, Inc.
6.56
-2.53%